New Phase III RISE Trial Data Supports Efficacy of Qutenza® for Post-Surgical Neuropathic Pain – Late-breaking data highlights significant pain relief in patients using Qutenza® – Qutenza® shows sustained effectiveness over a treatment period of up to 42 weeks – Findings presented at the 2026 IASP World Congress on Pain in Bangkok – Grünenthal reinforces commitment to addressing post-surgical…
No responses yet